Pipeline

September 2, 2019

Company	Drug/Device	Medical Condition	Status
CStone Pharmaceuticals	avapritinib	GIST	Phase 1 trial initiated
CStone Pharmaceuticals	CS3002	advanced solid tumors	Phase 1 trial initiated enrolling subjects in Australia
Alkahest	GRF6021	Primary hip or knee arthroplasty	Phase 2 trial initiated enrolling 45 subjects
Mag Force AG	NanoTherm therapy	Cancer lesions for prostate cancer	Phase 2 trial initiated enrolling 120 male subjects at the Texas Urology Group, the University of Texas, San Antonio and the University of Washington, Seattle
Aimmune Therapeutics, Inc.	AR201	egg allergy	Phase 2 trial initiated enrolling 84 children, adolescents and young adults ages 4 to 26 years of age with hen egg allergy at 15 sites in the U.S.
Fulcrum Therapeutics	Losmapimod (selective p38alpha/beta MAPK inhibitor)	facioscapulohumeral muscular dystrophy (FSHD)	Phase 2b trial initiated enrolling subjects with genetically confirmed FSHD
Mitsubishi Tanabe Pharma Corporation	ND0612	Parkinson's disease with motor fluctuations	Phase 3 trial initiated enrolling 300 subjects with PD experiencing motor fluctuations, whose symptoms are no longer controlled by conventional treatments at approximately 120 sites globally
VenatoRx Pharmaceuticals	cefepime/VNRX-5133	complicated urinary tract infection (cUTI)	Phase 3 trial initiated enrolling 582 adult subjects with cUTI, including acute pyelonephritis
DiscGenics, Inc.	IDCT	degenerative disc disease (DDD)	Fast Track designation granted by the FDA
CrystalGenomics, Inc.	CG-745	pancreatic cancer	Orphan Drug Designation granted by the FDA
Kyowa Kirin Co., Ltd.	NOURIANZ (istradefylline)	Parkinson’s disease	Approval granted by the FDA
Eli Lilly and Company	Taltz (ixekizumab) injection 80 mg/mL	active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA)	Approval granted by the FDA